Inactive Instrument

Bioadaptives Inc Stock OTC Bulletin Board

US09072U1079

BioAdaptives, Inc. operates in the health and wellness industry. The Companyâ€™s core business is to investigate, market and distribute natural plant, fungi, and algal based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties. Its products in development include a weight management supplement in a human clinical trial, Zeranovia. Zeranovia is made of natural ingredients and uses proprietary methods of optimizing the availability of nutrients in foods and beverages. Xcellara regenerative stem cell activator is in production. Xcellara is its regenerative wellness solution, to enhance performance, accelerate recovery, and revitalize health. PawPa Regen is the canine treat stem cell activator. PawPa Regen supports anti-aging and wellness. Its other products include MyndMed and Wynovia. MyndMed is designed to optimize multiple neurotransmitter systems and neuroprotective pathways.

Employees

Sector

Food Processing

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	295K 264K 245K 223K 421K 28.59M 423K 2.95M 1.16M 14.58M 1.11M 1.08M 46.77M	P/E 2024	-0.55x	P/E 2025	-0.14x
Enterprise Value	521K 466K 433K 394K 744K 50.46M 747K 5.21M 2.04M 25.73M 1.96M 1.92M 82.55M	EV / Sales 2024	55.1x	EV / Sales 2025	26.9x
Free-Float	5.04%	Yield 2024 *	-	Yield 2025	-

08-19	BioAdaptives, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-16	BioAdaptives Outlines Xcellara Platform Strategy And Announces Commercial Launch Of XcellaraHeart	CI
07-15	Bioadaptives Inc Announces Commercial Availability of Xcellaraheart Cardiovascular Wellness Formula	CI
06-25	BioAdaptives Completes MyndRenew Platform with TruShield Certification of MyndRenew Securing Full Wada Compliance	CI
05-20	Bioadaptives Inc Launches Myndsystem Platform	CI
05-15	BioAdaptives, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-06	BioAdaptives, Inc. Launches MyndRenew to Complete the 24-Hour Brain Performance Cycle	CI
04-28	BioAdaptives Inc Announces Launch of Myndsystem	CI
04-14	BioAdaptives, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-13	BioAdaptives, Inc. Auditor Raises 'Going Concern' Doubt	CI
11-14	BioAdaptives, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-07	BioAdaptives, Inc. Announces Commercial Launch of MyndMed Following Successful Pilot Testing	CI
25-08-20	BioAdaptives' MyndMed Receives Full Clearance from TruShield??, Meeting UFC and WADA Standards for Athlete Safety	CI

09-23	BioAdaptives Highlights Michael Bisping's MyndMed(TM) Routine in UFC 331 Pre-Show Instagram Video	AQ
09-03	BioAdaptives Confirms First Commercial Orders of XcellaraHeart(TM) and Outlines Capital Restructuring Progress	AQ
08-31	UFC Hall of Famer Michael Bisping Joins BioAdaptives to Champion MyndSystem(TM)	AQ
08-13	BioAdaptives, Inc. Announces CEO's Share Cancellation and Provides Capital Restructure Update	AQ
08-12	BioAdaptives Inc. Introduces XcellaraHeart(TM): the World's First Stem Cell Mobilizer with a Targeted Cardiac Homing Signal	AQ

Manager	Title	Age	Since
James Keener CEO	Chief Executive Officer	55	2024-05-20
Emily Harrison IRC	Investor Relations Contact	-	-
Antonina Nabokova PRN	Corporate Officer/Principal	63	-

Director	Title	Age	Since
Gimhana Dissanayake BRD	Director/Board Member	53	2024-05-29
James Keener CHM	Chairman	55	2024-05-20
Mark Frissora BRD	Director/Board Member	70	2025-02-02

Bioadaptives Inc Stock OTC Bulletin Board

Stocks

US09072U1079

Food Processing

Valuation: Bioadaptives Inc

Latest news: Bioadaptives Inc

Press Releases: Bioadaptives Inc

Quotes and Performance

Managers and Directors: Bioadaptives Inc

Special Foods & Wellbeing Products

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOADAPTIVES INC	+1.45%	+0.45%	-	-	295K
NESTLÉ S.A.	+0.05%	+1.68%	+0.57%	-26.39%	235B
MONDELEZ INTERNATIONAL, INC.	-0.43%	+3.82%	-1.69%	-5.06%	77.1B
GRUPO NUTRESA S. A.	+0.31%	+0.45%	+48.11%	+526.98%	45.58B
DANONE	-0.98%	-0.71%	-22.64%	+8.46%	42.28B
ARCHER-DANIELS-MIDLAND COMPANY	-3.10%	-0.70%	+31.31%	+7.74%	38.5B
THE HERSHEY COMPANY	+0.12%	+1.59%	-15.30%	-16.26%	32.7B
AJINOMOTO CO., INC.	+2.00%	+3.59%	+29.29%	+82.18%	32.55B
FOSHAN HAITIAN FLAVOURING AND FOOD COMPANY LTD.	-0.56%	+1.51%	-14.28%	-12.02%	28.9B
NESTLÉ INDIA LIMITED	+0.99%	+2.25%	+11.11%	+16.17%	26.56B
Average	-0.02%	+2.05%	+7.39%	+64.64%	62.18B
Weighted average by Cap.	-0.16%	+1.97%	+4.97%	+36.27%

	2024	2025
Net sales	12.67K 11.31K 10.53K 9.57K 18.08K 1.23M 18.15K 127K 49.64K 625K 47.57K 46.53K 2.01M	18.28K 16.32K 15.19K 13.81K 26.08K 1.77M 26.19K 183K 71.61K 902K 68.64K 67.14K 2.89M
Net income	-899K -803K -747K -679K -1.28M -87.02M -1.29M -8.99M -3.52M -44.37M -3.38M -3.3M -142M	-1.56M -1.39M -1.29M -1.18M -2.22M -151M -2.23M -15.58M -6.1M -76.87M -5.85M -5.72M -247M
Net Debt	206K 184K 171K 155K 293K 19.9M 295K 2.06M 806K 10.15M 772K 755K 32.56M	226K 202K 188K 171K 322K 21.87M 324K 2.26M 885K 11.15M 849K 830K 35.78M